No Data
No Data
Jenkem Technology (688356.SH): Some customers are using polyethylene glycol hydrogel for cartilage tissue repair.
On August 16th, Gelonhui reported that Jenkem Technology (688356.SH) said on the investor interaction platform that there are currently customers who use polyethylene glycol hydrogel for cartilage tissue repair. Such R&D projects are still in the early stage of research and development, and have not yet had a significant impact on the company's revenue. There are many factors involved in pharmaceutical R&D, and there is also a lot of uncertainty. Please be aware of investment risks. Based on years of profound understanding of drug delivery systems and sufficient accumulation of material research and development, the company actively aligns with new international technology trends, and focuses on building a broad polyethylene glycol material platform with application prospects and technological advancement, continuously.
Jenkem Technology (688356.SH): Currently, polyethylene glycol hydrogel has been used in the field of biological 3d printing.
Jenkem technology (688356.SH) stated on its investor interaction platform on August 9th that polyethylene glycol hydrogel has been applied in the field of biological 3D printing, and such customers have not yet had a significant impact on the company's sales revenue. In addition, based on the polyethylene glycol hydrogel 3D printing system, Jenkem invented a light initiator that is water-soluble, low-toxicity, and biocompatible.
Jenkem Technology (688356.SH): can provide a variety of different structured fatty acid side chain products.
On August 2nd, Gelunhui reported that jenkem technology (688356.SH) stated on their investor interaction platform that fatty acid side chains can be used for the modification of various polypeptide drugs, and the company can provide a variety of different structures of fatty acid side chain products, which can be customized based on the customer's needs. Currently, the jenkem technology-supported R&D projects of this type are in the early stage of development. Pharmaceuticals involve many factors, and there is also a lot of uncertainty. Please pay attention to investment risks. The company will closely monitor industry trends and technological innovations and plan the layout of related products according to market demand and the actual situation of the company.
Jenkem Technology (688356.SH): has repurchased 0.2440% of the company's shares.
On August 1st, Gelonhui announced that up to July 31st, 2024, Jenkem Technology (688356.SH) had accumulated to repurchase 0.147914 million shares of the company through the Shanghai Stock Exchange trading system through centralized bidding trading, accounting for 0.2440% of the company's total share capital. The highest price of the repurchase transaction was 75.05 yuan/share, the lowest was 62.85 yuan/share, and the total amount paid was 10,500,337.30 yuan (excluding taxes and fees).
After the Recent Decline, Jenkem Technology Co., Ltd. (SHSE:688356) CEO Xuan Zhao's Holdings Have Lost 11% of Their Value
Jenkem Technology (688356.SH): The three-component LNP developed in collaboration with Cansino Biologics Inc. can be licensed to other companies.
Jenkem Technology (688356.SH) stated on the investor interaction platform on July 16 that the three-component LNP developed in cooperation with Cansino Biologics Inc. can be licensed to other companies.
No Data